Nonsurgical management of mild primary hyperparathyroidism - A reasonable option

Clinical Endocrinology

Volumn 77, Issue 5, 2012, Pages 639-644

  Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; CALCIUM; CINACALCET; DENOSUMAB; ESTROGEN; PARATHYROID HORMONE; PLACEBO; VITAMIN D; ZOLEDRONIC ACID;

BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FRACTURE; FRAGILITY FRACTURE; GLUCOSE TOLERANCE; HUMAN; HYPERCALCEMIA; HYPERTENSION; KIDNEY FAILURE; MENTAL DISEASE; META ANALYSIS (TOPIC); MORBIDITY; NEOPLASM; NEPHROLITHIASIS; OSTEOLYSIS; PERCUTANEOUS VERTEBROPLASTY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIMIMETIC AGENTS; HUMANS; HYPERPARATHYROIDISM, PRIMARY; VITAMIN D;

EID: 84867280229     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2012.04501.x     Document Type: Review

References (64)

1. Fraser, W.D., (2009) Hyperparathyroidism. Lancet, 374, 145-158.
2. Bolland, M.J., Grey, A.B., Orr-Walker, B.J., et al,. (2008) Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. New Zealand Medical Journal, 121, 18-29.
3. Rubin, M.R., Bilezikian, J.P., McMahon, D.J., et al,. (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. Journal of Clinical Endocrinology and Metabolism, 93, 3462-3470.
4. Rao, D.S., Wilson, R.J., Kleerekoper, M., et al,. (1988) Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. Journal of Clinical Endocrinology and Metabolism, 67, 1294-1298. (Pubitemid 19012967)
5. Silverberg, S.J., &, Bilezikian, J.P., (2006) The diagnosis and management of asymptomatic primary hyperparathyroidism. Nature Clinical Practice Endocrinology and Metabolism, 2, 494-503. (Pubitemid 44353290)
6. Udelsman, R., Pasieka, J.L., Sturgeon, C., et al,. (2009) Surgery for asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. Journal of Clinical Endocrinology and Metabolism, 94, 366-372.
7. Yu, N., Donnan, P.T., &, Leese, G.P., (2011) A record linkage study of outcomes in patients with mild primary hyperparathyroidism: The Parathyroid Epidemiology and Audit Research Study (PEARS). Clinical Endocrinology, 75, 169-176.
8. Vestergaard, P., &, Mosekilde, L., (2003) Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. British Medical Journal, 327, 530-534.
9. Wermers, R.A., Khosla, S., Atkinson, E.J., et al,. (1998) Survival after the diagnosis of hyperparathyroidism: a population-based study. American Journal of Medicine, 104, 115-122. (Pubitemid 28117404)
10. Rejnmark, L., Vestergaard, P., &, Mosekilde, L., (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 96, 2377-2385.
11. Silverberg, S.J., Shane, E., Jacobs, T.P., et al,. (1999) A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. New England Journal of Medicine, 341, 1249-1255. (Pubitemid 29489739)
12. Grey, A.B., (1997) The skeletal effects of primary hyperparathyroidism. Baillieres Clinical Endocrinology and Metabolism, 11, 101-116. (Pubitemid 27309771)
13. Silverberg, S.J., Shane, E., de la Cruz, L., et al,. (1989) Skeletal disease in primary hyperparathyroidism. Journal of Bone and Mineral Research, 4, 283-291. (Pubitemid 19161996)
14. Silverberg, S.J., Shane, E., Dempster, D.W., et al,. (1999) The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. American Journal of Medicine, 107, 561-567.
15. Sankaran, S., Gamble, G., Bolland, M., et al,. (2010) Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 95, 1653-1662.
16. Khosla, S., &, Melton, J., 3rd, (2002) Fracture risk in primary hyperparathyroidism. Journal of Bone and Mineral Research, 17, N103-N107. (Pubitemid 35222321)
17. Grey, A., &, Bolland, M., (2010) Vitamin D: a place in the sun? Archives of Internal Medicine, 170, 1099-1100.
18. Lind, L., Jakobsson, S., Lithell, H., et al,. (1988) Relation of serum calcium concentration to metabolic risk factors for cardiovascular disease. British Medical Journal, 297, 960-963.
19. Cawthon, P.M., Parimi, N., Barrett-Connor, E., et al,. & for the Osteoporotic Fractures in Men Research G (2010) Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men. Journal of Clinical Endocrinology and Metabolism, 95, 4625-4634.
20. Yu, N., Leese, G.P., Smith, D., et al,. (2011) The natural history of treated and untreated primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study. Quaterly Journal of Medicine, 104, 513-521.
21. Bollerslev, J., Rosen, T., Mollerup, C.L., et al,. (2009) Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 94, 2255-2261.
22. Bolland, M.J., Grey, A.B., Gamble, G.D., et al,. (2005) Association between primary hyperparathyroidism and increased body weight: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 1525-1530. (Pubitemid 40464014)
23. Bolland, M.J., Grey, A.B., Ames, R.W., et al,. (2006) Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone, 38, 317-321. (Pubitemid 43255425)
24. Pitroda, A., Harris, S., &, Dawson-Hughes, B., (2009) The association of adiposity with parathyroid hormone in healthy older adults. Endocrine, 36, 218-223.
25. Paik, J.M., Farwell, W.R., &, Taylor, E.N., (2012) Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporosis International, 23, 1727-1736.
26. Ahlstro, T., Hagstro, E., Larsson, A., et al,. (2009) Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women. Clinical Endocrinology, 71, 673-678.
27. Grey, A., &, Reid, I., (1995) Body weight and bone mineral density in hyperparathyroidism. Annals of Internal Medicine, 123, 732.
28. Hinton, P.S., LeCheminant, J.D., Smith, B.K., et al,. (2009) Weight loss-induced alterations in serum markers of bone turnover persist during weight maintenance in obese men and women. Journal of the American College of Nutrition, 28, 565-573.
29. Reinehr, T., de Sousa, G., Alexy, U., et al,. (2007) Vitamin D status and parathyroid hormone in obese children before and after weight loss. European Journal of Endocrinology, 157, 225-232. (Pubitemid 47233129)
30. Bollerslev, J., Jansson, S., Mollerup, C.L., et al,. (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism, 92, 1687-1692. (Pubitemid 46997172)
31. Ambrogini, E., Cetani, F., Cianferotti, L., et al,. (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. Journal of Clinical Endocrinology and Metabolism, 92, 3114-3121. (Pubitemid 47236379)
32. Rao, D.S., Phillips, E.R., Divine, G.W., et al,. (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 89, 5415-5422. (Pubitemid 39518419)
33. Klazen, C.A.H., Lohle, P.N.M., de Vries, J., et al,. (2010) Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet, 376, 185-192.
34. Buchbinder, R., Osborne, R.H., Ebeling, P.R., et al,. (2009) A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. New England Journal of Medicine, 361, 557-568.
35. Kallmes, D.F., Comstock, B.A., Heagerty, P.J., et al,. (2009) A randomized trial of vertebroplasty for osteoporotic spinal fractures. New England Journal of Medicine, 361, 569-579.
36. Bilezikian, J.P., Khan, A.A., Potts, J.T., Jr., & on behalf of the Third International Workshop on the Management of Asymptomatic Primary H. (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. Journal of Clinical Endocrinology and Metabolism, 94, 335-339.
37. Bilezikian, J.P., Potts, J.T., Jr,., Fuleihan Gel, H., et al,. (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. Journal of Clinical Endocrinology and Metabolism, 87, 5353-5361. (Pubitemid 36034328)
38. Anonymous (1991) NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Annals of Internal Medicine, 114, 593-597.
39. Silverberg, S.J., Brown, I., &, Bilezikian, J.P., (2002) Age as a criterion for surgery in primary hyperparathyroidism. The American Journal of Medicine, 113, 681-684. (Pubitemid 36015805)
40. Khan, A.A., Bilezikian, J.P., &, Potts, J.T., Jr,. (2009) The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. Journal of Clinical Endocrinology and Metabolism, 94, 333-334.
41. Deaconson, T.F., Wilson, S.D., &, Lemann, J., Jr,. (1987) The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery, 102, 910-913. (Pubitemid 18010734)
42. Vestergaard, P., Mollerup, C.L., Frokjaer, V.G., et al,. (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. British Medical Journal, 321, 598-602.
43. Writing Group for the Women's Health Initiative (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 288, 321-333.
44. Khosla, S., (2009) Increasing options for the treatment of osteoporosis. New England Journal of Medicine, 361, 818-820.
45. FRAX: WHO fracture risk assessment tool. http://www.shef.ac.uk/FRAX
46. Garvan fracture risk calculator. http://www.garvan.org.au/promotions/ bone-fracture-risk/.
47. Collins, G.S., Mallett, S., &, Altman, D.G., (2011) Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFracture scores. British Medical Journal, 342, d3651.
48. Lodder, M.C., Lems, W.F., Ader, H.J., et al,. (2004) Reproducibility of bone mineral density measurement in daily practice. Annals of the Rheumatic Diseases 63, 285-289. (Pubitemid 38250672)
49. Gourlay, M.L., Fine, J.P., Preisser, J.S., et al,. (2012) Bone-density testing interval and transition to osteoporosis in older women. New England Journal of Medicine, 366, 225-233.
50. Grey, A.B., Stapleton, J.P., Evans, M.C., et al,. (1996) Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Annals of Internal Medicine, 125, 360-368. (Pubitemid 126449705)
51. Khan, A.A., Bilezikian, J.P., Kung, A.W.C., et al,. (2004) Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism, 89, 3319-3325. (Pubitemid 38951898)
52. Chow, C.C., Chan, W.B., Li, J.K.Y., et al,. (2003) Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 88, 581-587. (Pubitemid 36207794)
53. Cummings, S.R., Martin, J.S., McClung, M.R., et al,. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New England Journal of Medicine, 361, 756-765.
54. Black, D.M., Delmas, P.D., Eastell, R., et al,. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. New England Journal of Medicine, 356, 1809-1822. (Pubitemid 46698462)
55. Grey, A., Bolland, M.J., Horne, A., et al,. (2012) Five years of anti-resorptive activity after a single dose of zoledronate - results from a randomized double-blind placebo-controlled trial. Bone, 50, 1389-1393.
56. Peacock, M., Bilezikian, J.P., Klassen, P.S., et al,. (2005) Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 90, 135-141. (Pubitemid 40116646)
57. Peacock, M., Bolognese, M.A., Borofsky, M., et al,. (2009) Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. Journal of Clinical Endocrinology and Metabolism, 94, 4860-4867.
58. Marcocci, C., Chanson, P., Shoback, D., et al,. (2009) Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 94, 2766-2772.
59. Silverberg, S.J., Rubin, M.R., Faiman, C., et al,. (2007) Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 92, 3803-3808. (Pubitemid 47607626)
60. Rao, D.S., Honasoge, M., Divine, G.W., et al,. (2000) Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. Journal of Clinical Endocrinology and Metabolism, 85, 1054-1058. (Pubitemid 32269349)
61. Moosgaard, B., Christensen, S.E., Vestergaard, P., et al,. (2008) Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clinical Endocrinology, 68, 707-715. (Pubitemid 351533444)
62. Grey, A., Lucas, J., Horne, A., et al,. (2005) Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. Journal of Clinical Endocrinology and Metabolism, 90, 2122-2126. (Pubitemid 40586249)
63. Tucci, J.R., (2009) Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. European Journal of Endocrinology/European Federation of Endocrine Societies, 161, 189-193.
64. Eastell, R., Arnold, A., Brandi, M.L., et al,. (2009) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. Journal of Clinical Endocrinology and Metabolism, 94, 340-350.